Search "pharma competitive intelligence" and you find two things: expensive subscription dashboards you operate yourself, and bespoke consulting engagements that take weeks. Most of the spend buys capability, not the answer to your question. A dashboard can produce almost any figure once someone knows which figure to ask for, and a slow engagement often arrives after the decision has been made. Four tests tell you whether a competitive-intelligence brief will change a decision or just fill a folder.
Test 1: it answers a decision, not a topic
A brief worth commissioning is scoped to a specific commercial choice, not a subject area. "The CGRP market" is a topic; "which payer decision sets the value bar for our launch, and how much pricing runway it leaves" is a decision. The first returns a document; the second returns an answer you can act on. If the scope does not name the decision, the brief will not move it.
Test 2: every figure is traceable
Provenance is the product. Each material number should trace to a named primary source, an FDA record, a PMID-indexed paper, a ClinicalTrials.gov registration, or a live payer policy, and a figure that cannot be traced should be dropped, not estimated. This matters because a plausible-sounding statistic that turns out to be wrong in front of your payer or your leadership is not recoverable in the same meeting. Ask how a provider handles a number it cannot verify. "We drop it" is the right answer.
Test 3: the caveats are visible
A brief that hides uncertainty is selling confidence, not intelligence. Cross-trial efficacy figures should be labelled as cross-trial and never presented as a head-to-head, the trap in a crowded launch like IgA nephropathy; ranges should be shown as ranges rather than dressed up as false precision; and an estimate should be marked as an estimate. The visible caveat is a feature, because it is what lets you defend the number when someone tests it. A clean, uncaveated ranking is usually the tell that the hard question was skipped.
Test 4: you can act on it this week
Intelligence that arrives after the decision is history. A brief scoped to a live decision has to land inside the planning window, in a format your team can present without rebuilding it, PDF for the read, an editable model for the analyst, slides for the room. Speed is not a luxury here; it is the difference between intelligence that changes the call and a post-mortem on one already made.
Match the tool to the decision
If your team needs continuous monitoring across dozens of assets, a platform subscription may be right. If you need a defensible answer to one commercial question before a specific decision, a research-verified custom brief gets you there faster and cheaper. The four tests are how you tell which one you are actually buying.
AXLRx builds decision-scoped competitive-intelligence briefs, every figure traced to a live source or dropped. See a sample brief, or commission one scoped to your decision.